Ranbaxy Introduces Omeprazole 40mg Capsules
Posted on: Tuesday, 29 July 2008, 09:01 CDT
Ranbaxy Pharmaceuticals, a wholly owned subsidiary of Ranbaxy Laboratories, Gurgaon, India, has announced that under an agreement with AstraZeneca Pharmaceuticals it has launched an authorized generic of Omeprazole 40mg capsules in the US healthcare system.
Ranbaxy's Omeprazole 40mg is indicated for the treatment of acid-related disease, including gastric ulcer and Zollinger-Ellison syndrome.
Jim Meehan, vice president of sales and distribution at Ranbaxy Pharmaceuticals, said: "We welcome the opportunity to market an authorized generic of Omeprazole 40mg capsules that will be commercialized immediately to all classes of trade in the US healthcare system under the Ranbaxy label.
"We will offer this product as an affordable and accessible generic formulation to patients requiring this medication."
Source: Datamonitor
Related Articles
- Endo Pharmaceuticals CFO Resigns
- Watson Launches Omeprazole Delayed-Release Capsules, 40MG
- Amneal Pharmaceuticals Completes Acquisition of Liquid Form Generic Pharmaceuticals Manufacturing Plant
- Amneal Pharmaceuticals & Indoco Remedies Finalize Long Term Joint Venture Agreement to Develop and Market Generic Ophthalmic Pharmaceuticals
- Glenmark Cleared By FDA to Market Generic Pravachol
- Ranbaxy Granted FDA Approval to Market Atenolol Tablets
- Ranbaxy Wins FDA Approval for Generic Anti-Infective
- UBS Hosts Global Specialty Pharmaceuticals Conference
- Ranbaxy Acquires Belgian Generics Company
- Ranbaxy Gets OK to Appeal Lipitor Ruling
User Comments (0)
RSS Feeds